Why the study?
Induced pluripotent stem cell-cardiomyocytes from Newfoundland patients with arrhythmogenic cardiomyopathy had not yet been characterized.
Does GSK3 inhibition improve abnormal contractility and proarrhythmic tendencies in iPSC-CMs from Newfoundland patients with ACM?
Does GSK3 inhibition improve abnormal contractility and proarrhythmic tendencies in iPSC-CMs from Newfoundland patients with ACM?
GSK3 inhibition normalizes proarrhythmic tendencies in iPSC-CMs from Newfoundland patients with ACM, suggesting a potential therapeutic mechanism.
May support GSK3 inhibition in ACM; leaves open clinical translation from iPSC-CM models.
This is the first characterization of induced pluripotent stem cell-cardiomyocytes (iPSC-CMs) from Newfoundland patients with ACM. We find that ACM iPSC-CMs exhibit extreme proarrhythmic tendencies that can be normalized with GSK3 inhibition. Importantly, GSK3 inhibition is accompanied by a significant increase in key proteins, such as β-catenin and Lamin A/C, pointing toward a possible mechanism both for disease pathogenesis and therapy via GSK3 inhibitors.
No takes yet. Share an insight, caveat, or question.
Noort et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: